Is IQVIA (IQV) overvalued or fairly valued?

MarketChacha shows IQVIA's valuation in context — a forward P/E of about 14.2, a price-to-book of about 5.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of IQVIA (IQV)?

IQVIA last traded at $200.93 (-0.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

IQVIA

IQV · NYSE · Healthcare · United States

$200.93-0.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:38 PM

Snapshot

TickerIQV

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees93,000

HeadquartersDurham, United States

Market cap$33.5B

P/B5.4

Volume279.93K

Websitewww.iqvia.com

Filings tracked0

About IQVIA

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.1%
Institutions98.9%
Public & other0.0%

1,522 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.9.00%
Harris Associates L.P.7.30%
Vanguard Capital Management LLC6.61%
Vanguard Portfolio Management LLC4.54%
State Street Corporation4.48%
JPMORGAN CHASE & CO3.24%
Artisan Partners Limited Partnership3.03%
Geode Capital Management, LLC2.67%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $4.3B · EPS 3.24

Est. earnings growth +8.2%

Next fiscal year

Rev $18.3B · EPS 14.17

Est. earnings growth +10.7%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$154.5052-wk range$247.05

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about IQV

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.